RT Book, Section
A1 Damon, Lloyd E.
A1 Andreadis, Charalambos Babis
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193158638
T1 Stem Cell & Immune Cell Therapeutics
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193158638
RD 2024/04/25
AB Hematopoietic  stem  cell  transplantation  is  a  valuable  treatment  for  a  variety  of  hematologic  malignancies  and  a  few  nonhematologic  cancers  and  nonmalignant  conditions.  In  many  cases,  stem  cell  transplantation  offers  the  only  curative  option  and  can  be  a  life-saving  procedure.  Immune  effector  cell  (eg,  T-cell,  NK-cell)  therapy  is  an  emerging  approach  in  hematologic  and  solid  malignancies  that  utilizes  immune  cells  genetically  engineered  to  recognize  cancer-specific  epitopes  and  incite  an  immune  response  against  cancer.  Autologous-derived  T-cell  therapies  targeting  CD19  are  available  for  the  treatment  of  B-cell  non-Hodgkin  lymphomas  and  B-lymphoblastic  leukemia.  Autologous-derived  T-cell  therapies  targeting  BCMA  are  available  for  patients  with  plasma  cell  myeloma.